Estrogen effects on mammary epithelial and breast cancer (BC) cells are mediated by the nuclear receptors ERa and ERb, transcription factors that display functional antagonism with each other, with ERb acting as oncosuppressor and interfering with the effects of ERa on cell proliferation, tumor promotion and progression. Indeed, hormone-responsive, ERa þ BC cells often lack ERb, which when present associates with a less aggressive clinical phenotype of the disease. Recent evidences point to a significant role of microRNAs (miRNAs) in BC, where specific miRNA expression profiles associate with distinct clinical and biological phenotypes of the lesion. Considering the possibility that ERb might influence BC cell behavior via miRNAs, we compared miRNome expression in ERb þ vs ERbÀ hormone-responsive BC cells and found a widespread effect of this ER subtype on the expression pattern of these non-coding RNAs. More importantly, the expression pattern of 67 miRNAs, including 10 regulated by ERb in BC cells, clearly distinguishes ERb þ , node-negative, from ERbÀ, metastatic, mammary tumors. Molecular dissection of miRNA biogenesis revealed multiple mechanisms for direct regulation of this process by ERb þ in BC cell nuclei. In particular, ERb downregulates miR-30a by binding to two specific sites proximal to the gene and thereby inhibiting pri-miR synthesis. On the other hand, the receptor promotes miR-23b, -27b and 24-1 accumulation in the cell by binding in close proximity of the corresponding gene cluster and preventing in situ the inhibitory effects of ERa on pri-miR maturation by the p68/DDX5-Drosha microprocessor complex. These results indicate that cell autonomous regulation of miRNA expression is part of the mechanism of action of ERb in BC cells and could contribute to establishment or maintenance of a less aggressive tumor phenotype mediated by this nuclear receptor.
Estrogen effects on mammary epithelial and breast cancer (BC) cells are mediated by the nuclear receptors ERa and ERb, transcription factors that display functional antagonism with each other, with ERb acting as oncosuppressor and interfering with the effects of ERa on cell proliferation, tumor promotion and progression. Indeed, hormone-responsive, ERa þ BC cells often lack ERb, which when present associates with a less aggressive clinical phenotype of the disease. Recent evidences point to a significant role of microRNAs (miRNAs) in BC, where specific miRNA expression profiles associate with distinct clinical and biological phenotypes of the lesion. Considering the possibility that ERb might influence BC cell behavior via miRNAs, we compared miRNome expression in ERb þ vs ERbÀ hormone-responsive BC cells and found a widespread effect of this ER subtype on the expression pattern of these non-coding RNAs. More importantly, the expression pattern of 67 miRNAs, including 10 regulated by ERb in BC cells, clearly distinguishes ERb þ , node-negative, from ERbÀ, metastatic, mammary tumors. Molecular dissection of miRNA biogenesis revealed multiple mechanisms for direct regulation of this process by ERb þ in BC cell nuclei. In particular, ERb downregulates miR-30a by binding to two specific sites proximal to the gene and thereby inhibiting pri-miR synthesis. On the other hand, the receptor promotes miR-23b, -27b and 24-1 accumulation in the cell by binding in close proximity of the corresponding gene cluster and preventing in situ the inhibitory effects of ERa on pri-miR maturation by the p68/DDX5-Drosha microprocessor complex. These results indicate that cell autonomous regulation of miRNA expression is part of the mechanism of action of ERb in BC cells and could contribute to establishment or maintenance of a less aggressive tumor phenotype mediated by this nuclear receptor.
Introduction
Estrogens have a role in breast cancer (BC) pathogenesis and progression by controlling mammary cell proliferation and key cellular functions via the estrogen receptors (ERa and ERb: Heldring et al., 2007) . ERs are members of the nuclear receptors superfamily of ligand-dependent transcription factors that both regulate gene expression controlling the estrogen signal transduction cascade with distinct and even antagonistic roles. In hormoneresponsive, ERa-positive BC cells ERb inhibits estrogen-mediated cell proliferation by increasing the expression of growth-inhibitory genes and by interfering with activation of cell cycle and anti-apoptotic genes by ERa in response to 17b-estradiol (E2: Chang et al., 2006; Grober et al., 2011) . ERb is frequently lost in BC, where its presence generally correlates with a better prognosis of the disease (Sugiura et al., 2007) , is a biomarker of a less aggressive clinical phenotype (Novelli et al., 2008; Shaaban et al., 2008) and its downregulation has been postulated to represent a critical stage in estrogen-dependent tumor progression (Roger et al., 2001; Bardin et al., 2004) . Despite the direct relationships between estrogen and breast carcinogenesis, the divergent roles of the two ER subtypes in BC are not fully understood, mostly because they are complex, involving genomic and non-genomic actions, regulation of gene transcription and control of mRNA stability and translation efficiency.
MicroRNAs (miRNAs) are small (20-25 nt) noncoding RNAs that can regulate gene activity in a posttranscriptional manner. These molecules, frequently transcribed as polycistronic RNAs, are synthesized in the nucleus by RNA polymerase II or III as long primary transcripts (pri-miRNAs), that are then processed by the class-2 RNase-III Drosha (Han et al., 2004) in B70-nucleotide stem-loop RNAs (pre-miRNAs), that in turn are exported from nucleus to cytoplasm by exportin 5 and Ran-GTP (Kim et al., 2009) and cleaved by Dicer/TRBP endoribonuclease into an imperfect miRNA/miRNA* duplex (Chendrimada et al., 2005) . Only one strand of the duplex is finally selected to function as a mature miRNA, whereas the other (passenger) strand is typically degraded (Okamura et al., 2008; Newman and Hammond, 2010) . Mature miRNAs are then incorporated into an RNA-induced silencing complex, which binds to target mRNAs, determining gene silencing by either inhibition of translation or mRNA degradation (Newman and Hammond, 2010) . miRNAs have been shown to regulate a wide variety of cellular phenotypes, including neoplastic transformation, cell proliferation, differentiation and homeostasis (Garzon et al., 2009) and altered expression of these small RNAs contributes to tumorigenesis, as some of them can function as either tumor suppressors or oncogenes Croce, 2009) . Interestingly, in solid tumors, such as prostate, colon, stomach, pancreas, lung and breast, the spectrum of miRNAs expressed (miRNome) is different from that of the corresponding normal tissues (Volinia et al., 2006) , suggesting the involvement of miRNAs in transformed cell biology. Differential expression of miRNA genes was found associated with specific pathological features of BC, where distinct miRNA expression profiles in normal vs cancer tissue or between different molecular and clinical tumor subtypes appears to be the rule (Iorio et al., 2005; Lu et al., 2005; Blenkiron et al., 2007; Tavazoie et al., 2008) . There is increasing evidence, in fact, that specific miRNAs may be responsible at large for disease heterogeneity, functioning as regulators of tumorigenicity, invasion and metastasis (Tavazoie et al., 2008) . Moreover, genetic defects in key components of the miRNA biosynthetic pathway have been described in tumors (Hill et al., 2009; Melo et al., 2009 Melo et al., , 2010 , and several genes involved in BC progression have been identified as targets of miRNAs that, in turn, are found deregulated in BC cells (Garzon et al., 2009) .
Several evidences indicate that ERa is among the transcription factors regulating miRNA biogenesis in hormone-responsive BC cells (Bhat-Nakshatri et al., 2009; Castellano et al., 2009; Maillot et al., 2009; Yamagata et al., 2009; Cicatiello et al., 2010; Ferraro et al., 2010 Ferraro et al., , 2011 . More recently, global mapping of ERb binding to ERa-positive, hormone-responsive BC cells chromatin in vivo showed ERb interaction with several miRNA genes, suggesting the possible involvement of this receptor in hormonal control of small noncoding RNA biogenesis in this cell type (Grober et al., 2011) . Starting from this observation, we investigated here miRNA expression pattern in estrogen-responsive BC cell lines engineered to express full-length ERb and in primary-tumor samples selected according to the presence or absence of this nuclear receptor. Results indicate a role of ERb in the control of miRNA biogenesis and expression pattern in BC cells.
Results
ERb induces widespread changes in miRNA expression in hormone-responsive cells In order to investigate the role of ERb in BC, we generated MCF-7 cells stably expressing full-length human ERb (ERb-1) fused at the N-(N-TAP-ERb) or C-(C-TAP-ERb) terminus to a TAP tag in pTRE2pur-HA expression vector (Puig et al., 2001) . As shown in Figure 1a , the expression levels of C-TAP-ERb (two independent clones: lanes 2-3), N-TAP-ERb (lane 4) or C-TAP-ERa (used as control: lane 5) are comparable to those relative to endogenous ERa, as detected by WB under comparable test conditions, to avoid toxic and artifactual events consequent to overexpression of the exogenous protein. The functional integrity of tagged ERb was assessed by measuring their ability to counteract induction of ERE-TK-luciferase reporter-gene transcription by ligand-activated endogenous ERa. As shown in Figure 1b , cell expressing TAP-ERb show a marked reduction in E2-mediated activation of reportergene transcription compared with wt cells, a phenotype that could be almost completely recovered by stimulation with the ERa-selective ligand 4,4 0 ,4 00 -(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol (PPT). TAP-ERb effects on E2-induced MCF-7 cell proliferation and cell cycle progression were also investigated and the results, reported in Figures 1c and d , show that cells expressing exogenous ERb grow much slower in response to estrogen than wt or C-TAP-ERa cells, consequent to reduced G1-S transition (Figure 1d ). It is worth mentioning that the cell cycle inhibitory effects of ERb are well known (Heldring et al., 2007; Grober et al., 2011, and references therein) and are more evident at relatively higher concentrations of E2 (X10
À10
), compatible with the lower affinity of this ER subtype for the hormone (compare, for each cell clone, the S þ G2 fraction in hormone-stimulated vs -starved cells). The efficiency of PPT in promoting cell cycle progression (Figure 1d ) relates to its ability to promote ERamediated gene transcription (Figure 1b) , confirming the direct link between transcriptional activity of this receptor subtype and the mitogenic effects of estrogen (Cicatiello et al., 2010) . Gene-expression profiling of asynchronously growing cells showed no major differences between N-and C-TAP-ERb cells, whereas their transcriptomes were significantly different from that of C-TAP-ERa cells (Supplementary Figure S1) , confirming previous results obtained in E2-stimulated cells (Grober et al., 2011) . Based on these results, expression of the TAP-ERb fusion proteins appears to significantly affect ERa-mediated estrogen signal transduction to target genes and the cell cycle, confirming previous observations indicating that they are fully functional in vivo (Grober et al., 2011; Nassa et al., 2011) .
Multiple roles have been proposed for miRNAs in hormone-responsive BC, where the presence of ERb has been shown to associate with less aggressive disease forms. We decided to use our ERb-expressing cells to investigate potential links between ERb and miRNA activity in hormone-responsive BC cells, as these miRNA regulation by ERb in breast cancer O Paris et al represent a useful in vitro model to investigate the molecular mechanisms underlying the biological effects of this receptor subtype in hormone-responsive tumors. To this aim, total RNA was extracted from wt MCF-7, N-TAP-ERb, C-TAP-ERb (2 independent clones) and C-TAP-ERa cells. Global analysis of miRNome expression was peformed with microarrays detecting the vast majority of known and characterized miRNAs (Illumina MicroRNA Expression Beadchip, Illumina Italia, Milano, Italy) as described in Material and methods. Results indicates that expression of ERb has a deep impact on BC cell miRNome, as 84 miRNAs were found differentially expressed in three ERb þ vs two ERbÀ cell lines, whereas no significant differences could be detected among cells expressing the different tagged forms of ERb, or between C-TAP-ERa, wt and MCF7-TAP cells (not shown), that express only the TAP peptide and show no differences in ERa signaling with respect to wt cells (Ambrosino et al., 2010; Grober et al., 2011) . To validate this result, we performed miRNA expression profiling with a different microarray platform (Agilent Human microRNA Microarrays 18 Â 15 K v3, Agilent Technologies Italia, Milano, Italy) and compared the results obtained in the two experimental settings. As expected, we observed some differences between the two data sets, likely due to technical differences between the two microarrays platforms (in particular sensitivity and quality of the probes) and the two probe sets (Supplementary Materials and methods and data not shown). Nevertheless, 73 among the differentially expressed miRNAs identified with the Illumina platform were either fully confirmed with the Agilent array or, in some instances, could not be detected here due to a lower sensitivity of this platform. For this reason, we performed a further validation of the results obtained with the Illumina arrays analyzing by real-time RT-PCR (reverse transcriptase-PCR) the expression levels of 10 miRNAs selected according to their relative expression level, ranging from very low to high, and including also miRNA undetectable with Agilent arrays or differentially expressed between cell lines (except for miR-181c, that was not differentially expressed and is included as negative control). Results (reported in Supplementary Figure S2) show a very high correlation between rtPCR and Illumina array data (correlation coefficient: 0.76), indicating reliability of this microarray platform. The 73 differentially expressed miRNAs listed in Figure 2a and Table 1 were thus considered validated. To gather insights on the molecular mechanisms for ERb effects on miRNAs, expression profiling was carried out in both cell types after estrogen starvation. Under these conditions, no differences could be detected between ERb þ and ERbÀ cells (left panel in Figure 2b , referring to average values measured in ERbÀ vs ERb þ cell lines), indicating a key role of the liganded in determining the observed differences. For this reason, we next investigated whether expression of the 73 miRNAs identified in the E2 for 6-72 hrs before miRNA analysis. Results displayed in Figure 2b (right panel) show that all investigated miRNAs respond to the hormone in a time-dependent manner. Although kinetics and extent of miRNA response to the stimulus were comparable between the two ERb þ cell lines, they were significantly different in ERb þ vs ERbÀ (C-TAP-ERa) cells. Direct comparison of the data from the two cell types indicates that the differences in steady-state miRNA levels consequent to ERb expression are due to ERb antagonism upon ERa activity or to a specific effect of ligandactivated ERb. As shown in Supplementary Figure S3 , for example, expression of hsa-miR30a* and, to a lesser extent, hsa-miR30a shows a time-dependent decrease following E2 stimulation only in ERb þ cells, whereas it is unaffected by the stimulus in the absence of ERb. On the contrary, hsa-miR-23b and -23b*, hsa-miR-27b and27b* and hsa-miR-24 and -24-1* levels decrease in the presence of E2 in ERbÀ whereas they increase in ERb þ cells. The putative mRNA targets of the miRNAs regulated by ERb were searched with TargetScan and, subsequently, analyzed for Gene Ontology term overrepresentation, in order to identify biological processes likely to be influenced by this ER subtype via miRNAs. In this way, several cellular processes were found downstream of ERb-responsive miRNAs, including those known to be affected by ERb, such as response to hormonal stimuli, regulation of transcription and cell proliferation and others that represent key cellular processes in malignant cells, including cell motility, migration, adhesion, differentiation and fate determination, and are targeted by regulatory cascades in cancer cells (Supplementary Figure S4) . The data described above were obtained in vitro in a BC cell model that, although it has been shown to reflect miRNA regulation by ERb in breast cancer O Paris et al only in part the complexity of the hormone-responsive phenotype, in several cases provided molecular insights that could be validated and find application in the clinical setting. For this reason, we considered these evidences as an indication that ERb might indeed influence miRNome activity also in primary breast tumors. To this end, BC samples were selected, among those originally included in the study reported by Novelli et al. (2008) , for presence or absence of ERb expression according to immuno-histochemistry (Supplementary Figure S5) . Tumors were divided in two groups of 22 ERb þ and 18 ERbÀ tumors, respectively, that did not show significant differences from each other with respect to key clinical and molecular parameters, summarized in Supplementary Table S1 , with the notable exception of the presence of lymphnodal metastases and a worst tumor grading for ERbÀ tumors. RNA was extracted from formalin-fixed, paraffin-embedded tissues and that from 17 ERb þ and 19 ERbÀ tumors was of quality and concentration apt to perform miRNA expression profiling as described (Ravo et al., 2008) . This led to the identification of 67 miRNAs, whose expression level discriminates ERb þ from the ERbÀ breast tumors, including 10 miRNAs that were found differentially expressed also in ERb þ vs ERbÀ BC cells in vitro (Figure 2c and Supplementary  Table S2 ). These results confirm those obtained in cell lines (Figures 2a and b) , pointing to a role of ERb in the control of BC miRNome and thereby indicating that miRNAs are integral components of the gene regulation cascade mediating the effects of this nuclear receptor in tumor cells.
Direct regulation of miRNA biogenesis by hormone-activated ERb in BC cells
Mature miRNA expression can be regulated through control of either transcription or one of the key steps of primary transcript (pri-miR) maturation. We analyzed by chromatin immunoprecipitation sequencing (ChIPSeq) the entire ERa and ERb cistromes in the ERb þ (Grober et al., 2011) and ERbÀ cells (Cicatiello et al., 2010) upon E2 stimulation. Aligning ER-binding sites and miRNA gene positioning in the genome we observed that several miRNA-encoding genes differentially expressed in ERb þ vs ERbÀ cell lines (Supplementary Table S3A ) and/or mammary tumors Table S3B ) display ER-binding sites within 10 kb of the transcription unit, including sites where both ERs can be found together, likely associated in heterodimers. This finding suggested us the possibility that miRNA gene activity could be modulated in BC cells by an interplay of the two ER subtypes bound to chromatin, with ERb antagonizing ERa-mediated regulation of pri-miR biosynthesis and/or maturation rate.
To verify this possibility, we choose to investigate in detail differences in miRNA precursor levels in ERb þ vs ERbÀ cells following stimulation with E2, focusing on miR-30a gene and the miR-23b/27b/24-1 chromosomal cluster. The first was selected as it encodes two miRNAs (miR-30a and -30a*) that are downregulated by estrogen in ERb þ cells only (Supplementary Figure  S3) and it shows two binding sites for ERb in close proximity -one upstream and one downstream-of the transcription unit, but no ERa sites (Figures 3a and b) . The second caught our attention, instead, as it shows sites for both receptors (Figure 4a and Supplementary Figure S6 ) and it encodes three distinct couples of miRNAs, all accumulating in ERb þ cells and decreasing in ERbÀ cells in response to the hormone (Supplementary Figure S3) . Interestingly, in both cases the effect of the hormone was more evident on the 'star' strand that, for this reason, led us first to their identification ( Figure 2a ) and was routinely used here to monitor ERb effects. The results relative to the miR-30a locus are reported in Figure 3 and show that ERb binding results in a significant reduction of pri-, pre-and mature miR-30a levels following E2 stimulation, detectable already after 2 h (Figures 3c-e) , to indicate that the predominant effect of ligand-activated ERb is to trans-repress basal gene transcription by direct binding to this transcription unit. Noteworthy, activation of ERa alone (wt cells) did not affect miR-30a biogenesis, in agreement with the lack of binding of this receptor to the locus (Figure 3a) . When combined, these results indicate a specific and direct role of ERb in repression of miR-30a expression in BC cells, possibly mediated by promoter transrepression. This could be due to direct transcriptional repression, via recruitment of a repressor complex to the chromatin by ligand-activated ERb, or, alternatively, to inhibition of gene trans-activation caused by tethering of ERb to a transcription factor constitutively bound to the locus, resulting in displacement or inhibition of an activator complex. The latter possibility, that could explain also lack of ERa binding to such regulatory site, is worth investigating further, extending the analysis Our attention focused next on the miR-23b/27b/24-1 cluster on chromosome 9, whose organization is showed in Figure 4a . In this case, both ERb-and ERa-binding sites are detected. Noteworthy, the two ERa-binding sites identified by ChIP-Seq were also found by ChIPon-chip in an independent study (Hurtado et al., 2008) and binding of the two ERs to both sites identified here in ERb þ cells was confirmed by ChIP (Supplementary Figure S6) . The effects of ERb in regulation of the first step in miRNA biogenesis were investigated by measuring changes in pri-miR expression in control (wt), N-TAP-and C-TAP-ERb cells before and after E2 stimulation. Results show that in the absence of ERb, estrogen stimulation did not influence primary-transcript levels, assessed by both quantitative real-time rtPCR and RNA-expression profiling (c9orf3 RNA; Figure 4b and Cicatiello et al., 2010) . On the other hand, a slight but reproducible accumulation of pri-miR-23b/ -27b/-24-1 was detectable in ERb þ cells already 2 h after E2 (Figure 4b ). We next measured the intracellular concentration of the individual pre-miR deriving from this primary transcript (pre-miR-23b, -27b and -24-1) in both cell types and the results obtained were surprisingly very different. Indeed, as shown in Figure 4c , whereas stimulation with E2 of ERbÀ cells caused a substantial loss of pre-miR (ranging from À20 to À75%), the same treatment caused instead accumulation of these premiRs in ERb þ cells. This was reflected in comparable changes in expression of the corresponding mature miRNAs for up to 72 h after E2 stimulation (Figure 4d and Supplementary Figure S3) . These results indicate that the presence of ERb in ERa-expressing, estrogenresponsive BC cells can modify substantially the response of miRNA genes to hormonal stimulus. In the case of the miR-23b/27b/24-1 gene cluster, this results from changes in pri-miR maturation, rather than synthesis, leading to increase in pre-miR biosynthesis in the presence of chromatin-bound ERb.
ERb interferes with ERa-mediated recruitment of Drosha in inactive chromatin-bound complexes Yamagata et al. (2009) reported ERa-mediated regulation of miRNA maturation by direct interaction in the nucleus of ERa with a protein complex comprising Drosha and the DEAD box RNA helicase p68/DDX5, resulting in inhibition of pri-to pre-miRNA conversion by Drosha. We thus considered the possibility that the enhancing effect of ERb on pri-miR-23b/-27b/-24-1 maturation shown in Figure 4 could result from competition for binding of the ERa-p68-Drosha complex to this locus by ERb, as recently described for other target genes (Grober et al., 2011) , thereby preventing the inhibitory effect of ERa on nascent pri-miR maturation.
In both cases, we should expect inhibition of ERamediated p68/DDX5-Drosha recruitment to miR-23b/-27b/-24-1 chromatin by ERb. Indeed, this appears to be the case, as E2-induced p68/DDX5 and Drosha binding to ERb-G9242 and ERb-G9242 chromatin sites was strongly reduced in C-TAP-ERb compared with wt cells, concomitant with a reduction of ERa and appearance of ERb (upper panel of Figure 5a and data not shown). It is worth mentioning that binding of ERa to chromatin in ERb þ cells occurs mainly via heterodimerization with ERb (Grober et al., 2011) . ERb-mediated inhibition of p68/DDX5 binding could be observed also at the ERb-G5984 site of the TFF1/pS2 gene promoter, (Grober et al., 2011) .
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O Paris et al although Drosha could not be detected tethered to this site under any condition (lower panel of Figure 5b ), suggesting that association of this enzyme to chromatin may be promoted by ERa only at sites of pri-miR synthesis, where Drosha could be 'locked' in an inactive complex comprising ERa and the hairpin structure of the nascent pri-miR. Concerning the nature of the physical interaction between ERa and Drosha, it was suggested that this is mediated by p68/p72 RNA helicases (Yamagata et al., 2009) . Interestingly, a systematic analysis of the ERb interactome of MCF-7 cell nuclei failed to identify p68/ DDX5 binding to this receptor subtype as well as to ERa/ERb heterodimers, suggesting that the presence of ERb could determine inhibition of p68/DDX5-mediated sequestering of Drosha to the chromatin in an inhibitory complex. This possibility would provide a rationale for the ChIP results obtained in ERb þ cells, where we failed to detect these two proteins in the presence of both ERs (Figure 5a ). To verify this possibility, we performed co-purification analysis of all these proteins in nuclear extracts from wt, C-TAP-ERa or C-TAPERb cells. The two ERs were adsorbed to Sepharosebound IgG via their TAP tag, as described (Ambrosino et al., 2010; Nassa et al., 2011) . As shown in Figure 5b , Drosha and p68/DDX5 could be co-purified with ERa but not with ERb, demonstrating that ERb is unable to bind these proteins. It is worth mentioning that as under these experimental conditions ERa co-purifies with C-TAP-ERb and lower section of Figure 5b ), ERa/ERb heterodimers do not bind Drosha and p68/DDX5.
Discussion
The results described here demonstrates that ERb controls synthesis, maturation and steady-state levels of a significant number of miRNAs in BC cells by interfering with ERa activity or acting autonomously, as demonstrated here for the miR-23b/-27b/-24-1 cluster and the miR-30a gene, respectively. This, in turn, determines a profound effect on miRNome expression and activity in tumors expressing ERb, which could help explain their less aggressive clinical phenotype (Novelli et al., 2008; Shaaban et al., 2008) . Identification of the intracellular targets of these ERb-regulated miRNAs, and the effects they exert on key cellular functions of BC cells, will now provide a new venue to understand the pleiotropic role of this oncosuppressive factor in breast carcinogenesis and tumor progression. Furthermore, it is reasonable to conceive that proteins encoded by the mRNAs targeted by these miRNA may represent molecular markers exploitable for prognostic evaluation of primary breast tumors or for prediction of the disease responsiveness to hormonal therapy.
Materials and methods
Cell Culture, transient transfection and cell cycle analyses Human hormone-responsive BC cells MCF-7 Tet-Off (Clontech-Takara) expressing TAP (control cells), C-TAPERa, C-TAP-ERb or N-TAP-ERb were described previously (Ambrosino et al., 2010; Nassa et al., 2011) . They were propagated, hormone starved and analyzed for estrogen signaling, cell cycle progression and cell proliferation as described earlier (Cicatiello et al., 2000; Grober et al., 2011) .
RNA purification
Total RNA was extracted from hormone-starved ( þ EtOH, ÀE2) or stimulated ( þ E 2 ) cell cultures as described previously (Cicatiello et al., 2004) . FFPE tumor samples were cut in 5-mm-thick sections on a microtome with a disposable blade. RNA was extracted from three and eight sequential sections as described (Ravo et al., 2008) . RNA concentration in each sample was determined with a NanoDrop-1000 spectrophotometer (Thermo Fisher Scientific Italy, Cinisello Balsamo, Italia) and quality assessed with the Agilent 2100 Bioanalyzer and Agilent RNA 6000 cartridges (Agilent Technologies). For microarray analysis, RNAs extracted from replicate samples of the same tumor were pooled. 3) and IgG-Sepharoseaffinity-purified nuclear extracts (lanes 4-6) from wt (lanes 1 and 4), C-TAP-ERa (lanes 2 and 5) or C-TAP-ERb (lanes 3 and 6) cells, probed with the indicated antibodies. Asterisks mark non-specific bands.
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Microarray analyses
See Supplementary Materials and methods.
Protein-complex immunoprecipitations and analysis
Cells were hormone starved for 5 days and following stimulation with 10 À8 M E2 for 2 h, nuclear proteins were extracted and incubated with IgG-Sepharose beads (GE Healthcare, Milano, Italy) for 4 h at 4 1C, as described earlier (Ambrosino et al., 2010) . Affinity-purified complexes were resuspended in SDS sample buffer (Invitrogen Life Technologies Italia, Milano, Italy) and analyzed by SDS-PAGE and western blotting by using anti-TAP (CAB1001, Open Biosystems, Euroclone Spa, Milano, Italy), anti-ERa (sc-543, Santa Cruz Biotechnology), anti-Drosha (ab12286, Abcam, Cambridge, UK) and anti-DDX5 (ab21696, Abcam) antibodies. The primary antibodies were detected with a horseradish peroxidase-conjugated anti-rabbit antibody (GE Healthcare) and revealed by chemiluminescence and autoradiography.
Chromatin immunoprecipitation
Cells were hormone deprived for 4 days and chromatin was extracted from replicate samples before (ÀE2) or 45 min after stimulation with E2 as described previously (Cicatiello et al., 2010; Grober et al., 2011) . Chromatin samples were incubated at 4 1C overnight with Abs against the C-(HC-20, from Santa Cruz Biotechnology, Europe) or N-(18-32, Sigma Aldrich Italia, Milano, Italy) terminus of human ERa, anti-Drosha (ab12286, Abcam, used as described by Nakamura et al. (2007) , anti-DDX5 (ab21696, Abcam) or, for TAP-ERb, with IgG Sepharose 6 fast Flow (GE Healthcare) as described earlier (Grober et al., 2011) . As control, aliquots of the same chromatin were processed in the same way but Abs were omitted from the incubation mixtures ( þ E2/-Abs) or, where required, underivatized Sepahrose was used.
Quantitative real-time rtPCR Total RNA was extracted from cell lines (as described before) after stimulation for 2 h and 4 h with10 À8 M E2. For miRNA analysis, mature miRNA was reverse transcribed using a miRNA-specific stem-loop reverse transcriptase and real-time PCR was performed using Taqman microRNA assays (Assay ID: 2822 , 416, 2439 , 2445 , 2441 , 2126 , 2174 , 2440 , 2333 Applied Biosystems Italia, Monza, Italy) according to the manufacturer's instruction. RNU49 was used as an internal control to normalize all data using the Taqman RNU49 assay (Applied Biosystems Italia). RNU49 was unaffected by hormone treatment. For pre-miRNA and pri-miRNA analysis, RNA was reverse transcribed using Quantitect Rev. Transcription kit (Qiagen Italy, Milano, Italia) and real-time PCR was performed in triplicates in three independent experiments using Power Syber Green PCR Master Mix (Applied Biosystems Italia) and normalized to U6 snRNA. All the real-time PCR were performed on a MJ Research PTC-200 Opticon Instrument (MJ Research, Waltham, MA, USA). Primers used are listed in Supplementary Table 4 .
ChIP-Seq data analysis For ER-binding-site mapping in genome, ChIP-Seq data relative to ERb (Grober et al., 2011;  accession number E-MTAB-345) and ERa (Cicatiello et al., 2010;  accession number E-MTAB-131) were analyzed as follows. Enriched ChIP-Seq peaks were identified using FindPeaks (Fejes et al., 2008) , with a subpeaks value of 0.5. To select only highly relevant sites, the statistical cut-off of the first quartile was applied. The binding sites supported by a number of tags lower than 25% of the range of the values was discarded. This led to re-mapping of ERb-binding sites (renumbered here from ERb_G1 to ERb_G12430); for ERa-binding sites, numbering was the same as previously described (Cicatiello et al., 2010) .
miRNA target prediction and functional analysis of their putative mRNA targets For comprehensive prediction of miRNA-target genes, we used TargetScan, release 5.1 (http://www.targetscan.org). To identify statistically overrepresented 'biological process' gene ontology terms among sets of selected mRNA target, we used the Database for Annotation, Visualization and Integrated Discovery (DAVID, http://david.abcc.ncifcrf.gov/) functional annotation tool (Dennis et al., 2003; Huang et al., 2009) . To this aim, we used as background data coming from gene expression-profiling experiments performed on the same cell line and under the same experimental conditions used in this study.
Immunohistochemistry See: Supplementary Materials and methods.
BC samples clinical hallmarks
For the purpose of this study, 40 breast carcinomas were selected from a series of 936 cases with a median follow up (FU) of 50 months (min 1-max 108) subjected to breast surgery at the Regina Elena Cancer Institute between 2001 and 2005 (Novelli et al., 2008) . Of these, 22 were ERb þ without any recurrence, whereas 18 were ERbÀ and presented local or distant metastasis. In these patients, ERb expression was routinely determined at the time of surgical treatment along with other conventional biological factors namely ERa and progesterone receptors (PgR), HER2 and Ki-67, before any adjuvant therapy was planned. As showed in Supplementary Table S1, the group included 37 (92.5%) invasive ductal carcinomas and 3 (7.5%) invasive lobular carcinomas. Among these, 28 (70%) were pT1, 9 (22.5%) pT2 and 3 (7.5%) pT3-4, 27 (67.5%) were node negative and 13 (32.5%) were node positive, 29 (72.5%) G1-2 and 11 (27.5%) G3. ERa was positive in 37 tumors (92.5%) and negative in 3 (7.5%), PgR was positive in 31 tumors (77.5%) and negative in 9 (22.5), HER2 was positive in 12 tumors (30%) and negative in 28 (70%) and Ki-67 was positive in 16 tumors (40%) and negative in 24 (60%). Tumors were graded according to Bloom and Richardson and staged according to the Unione Internationale Contre le Cancer tumor-node-metastasis system criteria, and histologically classified according to the World Health Organization (Tavassoli and Devilee, 2003) . In the selected group, ERb þ was significantly associated to negative lymphnodes (Po0.0001) and low tumor grade (G1-2) (P ¼ 0.03) whereas, as already described on a large series of BC patients, (Novelli et al., 2008) 
